Isabelle Mahé: Cancer Site, Bleeding Risk, and Reduced-Dose Apixaban in Cancer-Associated Thrombosis
Isabelle Mahé, Head of Internal Medicine at Louis Mourier Hospital, APHP at Paris Cité University, shared on LinkedIn about a recent article she and her colleagues co-authored, adding:
”Bleeding risk varies according to solid cancer site, with a low risk of CRB in breast cancer (6·2%) and a narrow range across other solid tumours (15·4–18·5%) (original Article recently published in The Lancet Haematology)
Please read our reply just published in The Lancet Haematology!
In patients with CAT receiving extended treatment, reduced-dose apixaban is non inferior to full dose apixaban, and is associated with a significant 25% reduction in the risk of Clinically Relevant Bleeding (APICAT study published in NEJM Group)”
Title 1: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial
Authors: Isabelle Mahé, Céline Chapelle, Philippe Girard, Marc Carrier, Luis Jara Palomares, Charles-Marc Samama, Hélène Helfer, Grigoris Gerotziafas, Silvy Laporte, Eric Vicaut, Patrick Mismetti
Read the Full Article on The Lancet Haematology
Title 2: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
Authors: Isabelle Mahé, Marc Carrier, Didier Mayeur, Jean Chidiac, Eric Vicaut, Nicolas Falvo, Olivier Sanchez, Claire Grange, Manuel Monreal, Juan J. López-Núñez, Remedios Otero-Candelera, Grégoire Le Gal, Erik Yeo, Marc Righini, Helia Robert-Ebadi, Menno V. Huisman, Frederikus A. Klok, Peter Westerweel, Giancarlo Agnelli, Cecilia Becattini, Aristotelis Bamias, Kostas Syrigos, Sebastian Szmit, Adam Torbicki, Peter Verhamme, Anthony Maraveyas, Alexander T. Cohen, Cihan Ay, Céline Chapelle, Guy Meyer, Francis Couturaud, Patrick Mismetti, Philippe Girard, Laurent Bertoletti, Silvy Laporte
Read the Full Article on NEJM
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 7, 2026, 15:10Mrunalini Dandamudi: Perspective on Drug Coated Balloons in Coronary In-Stent Restenosis
-
Mar 7, 2026, 14:58Nicole Juffermans: Comparing the Effect of Plasma Versus Clear Fluids on Intravascular Volume
-
Mar 7, 2026, 14:55Alfadil Haroon: New Genetic Insights into Bone Marrow Failure Syndromes
-
Mar 7, 2026, 14:48Shaine Morris: Save the Date for the Texas Children’s Hospital Second Pediatric Aortopathy Symposium
-
Mar 7, 2026, 14:46Ahmad Hazri Mohamed Aris: Strengthening Bleeding Disorders Care Through WFH PACT 2026–2030
-
Mar 7, 2026, 14:42Megan Adediran: When Should Heavy Bleeding Stop Being Called Normal?
-
Mar 7, 2026, 14:41Heghine Khachatryan: Best-Practice Recommendations for Implementing Shared Decision-Making in Hemophilia Care
-
Mar 7, 2026, 14:37Julie Kennedy Lesch: Driving Progress for People Living with Sickle Cell Disease
-
Mar 6, 2026, 16:51Priya Reehal: Highlighting The Central Role of Nurses in Cardio-Oncology